Loading organizations...
Loading organizations...
Oncology drug discovery focused on targeted antibody-drug conjugates.
ADC Therapeutics has raised $726.0M across 8 funding rounds.
ADC Therapeutics has raised $726.0M in total across 8 funding rounds.
ADC Therapeutics has raised $726.0M in total across 8 funding rounds.
ADC Therapeutics's investors include TCGX, Redmile Group, Overland Pharmaceuticals, Deerfield Management, AstraZeneca, Auven Therapeutics, Wild Family Office, Peter Corr, Michael Forer, Bahija Jallal.
ADC Therapeutics has raised $726.0M across 8 funding rounds. Most recently, it raised $60.0M Other Equity in October 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 13, 2025 | $60.0M Other Equity | TCGX | Redmile Group |
| Dec 14, 2020 | $50.0M Other Equity | Overland Pharmaceuticals | |
| May 1, 2020 | $115.0M Other Equity | Deerfield Management | |
| Jun 12, 2019 | $76.0M Series E Extension | ||
| Oct 23, 2017 | $200.0M Other Equity | AstraZeneca, Auven Therapeutics, Redmile Group, Wild Family Office | |
| Oct 27, 2016 | $105.0M Other Equity | AstraZeneca, Peter Corr, Wild Family Office | |
| Sep 2, 2015 | $80.0M Other Equity | AstraZeneca, Peter Corr | |
| Oct 15, 2013 | $40.0M Other Equity | Michael Forer, Bahija Jallal |